lapatinib has been researched along with tamoxifen in 38 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (tamoxifen) | Trials (tamoxifen) | Recent Studies (post-2010) (tamoxifen) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 20,630 | 2,227 | 6,256 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (18.42) | 29.6817 |
| 2010's | 25 (65.79) | 24.3611 |
| 2020's | 6 (15.79) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Liu, Y; Xu, Z; Zhao, SJ | 1 |
| Afratis, K; Gavras, H; Karamanos, NK; Koutsakis, C; Leonardi, S; Papaioannou, D; Piperigkou, Z; Rassias, G; Rigopoulou, D; Vachlioti, E | 1 |
| Blackwell, K; Chen, S; Chu, I; Slingerland, J | 1 |
| Awada, A; Cardoso, F; de Azambuja, E; Dinh, P; Gil, T; Piccart-Gebhart, M; Widakowich, C | 1 |
| Boughey, JC; Brandt, KR; Degnim, AC; Dy, GK; Goetz, MP; Ingle, JN; Perez, EA; Pruthi, S; Reynolds, CA; Schomberg, PJ | 1 |
| Audhuy, B; El-Hariry, I; Gardner, JP; Gore, M; Harper, P; Hawkins, R; Machiels, JP; Pétavy, F; Ravaud, A; Rolland, F; Schöffski, P; von der Maase, H; Zantl, N | 1 |
| Cameron, DA; Stein, S | 1 |
| Fricker, J | 1 |
| Oestreicher, N | 1 |
| Bono, P; Joensuu, H | 1 |
| Crown, J; Duffy, MJ; O'Donovan, N | 1 |
| A'Hern, R; Anderson, H; Bliss, J; Dowsett, M; Dunbier, A; Evans, A; Ghazoui, Z; Iskender, A; Johnson, L; Pinhel, I; Robertson, J; Robison, L; Salter, J; Skene, T; Smith, I; Wilcox, M | 1 |
| Batra, SK; Chen, AC; Creighton, CJ; Gutierrez, MC; Huang, C; Lopez-Tarruella, S; Massarweh, S; Migliaccio, I; Osborne, CK; Rimawi, M; Schiff, R; Wang, YC | 1 |
| Ito, Y | 1 |
| Alici, S; Arslan, UY; Bilici, M; Boruban, C; Buyukberber, S; Dayan, A; Demir, L; Durnalı, AG; Elkiran, ET; Geredeli, C; Gumusay, O; Inal, A; Isikdogan, A; Kaplan, MA; Koca, D; Kocer, M; Kucukoner, M; Mert, AG; Ozkan, M; Suner, A; Tarhan, MO; Unal, OU; Urakci, Z; Yaman, S; Yildiz, R | 1 |
| Dorssers, LC; Foekens, JA; Godinho, MF; Look, MP; Petricoin, EF; Sieuwerts, AM; Sleijfer, S; van Agthoven, T; Wulfkuhle, JD | 1 |
| Accolla, ML; Castelli, F; Celia, C; Ferrari, M; Fresta, M; Grattoni, A; Paolino, D; Sarpietro, MG | 1 |
| Brown, C; De Souza, P; Fox, P; Gebski, V; Hudson, M; Lee, CK; Lord, S | 1 |
| Mehta, A; Tripathy, D | 1 |
| Fu, X; Giuliano, M; Klinowska, T; Morrison, G; Nanda, S; Osborne, CK; Rimawi, MF; Schiff, R; Shea, M; Wang, T | 1 |
| Awada, A; Bogaerts, J; Brain, E; Cardoso, F; Fumoleau, P; Hayward, L; Koch, KM; Lokiec, F; Marréaud, S; Rezai, K; Werutsky, G | 1 |
| Piccart, M; Sonnenblick, A | 1 |
| Abt, MA; Bruce, JS; Ghatnekar, GS; Grek, CL; Rhett, JM; Yeh, ES | 1 |
| Matevossian, A; Resh, MD | 1 |
| Ali, HR; Bentley, D; Caldas, C; Chin, SF; Contente-Cuomo, T; Dawson, SJ; Farahani, H; Gale, D; Grant, J; Humphray, S; Kingsbury, Z; Marass, F; Murtaza, M; Pogrebniak, K; Provenzano, E; Rosenfeld, N; Rueda, OM; Shah, P; Shah, SP; Shumansky, K; Tsui, DWY; Wallis, M | 1 |
| Choi, J; Kim, A; Kim, C; Kim, J; Lee, J | 1 |
| Chan, EC; Chan, JC; Lim, P; Ong, PS; Teng, PX | 1 |
| Hu, Y; Lee, S; Li, L; Lin, L; Schiff, R; Tan, Y; Veeraraghavan, J; Wang, X; Wang, XS | 1 |
| Kim, S; Kwon, YS; Nam, KS | 1 |
| Jackson, DB; Kim, S; Lahu, G; Lesko, LJ; Soldatos, TG; Trame, MN; Vakilynejad, M | 1 |
| Ito, Y; Kondo, M; Koseki, T; Tanaka, J; Yamada, S | 1 |
| Acconcia, F | 1 |
11 review(s) available for lapatinib and tamoxifen
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
Topics: Antineoplastic Agents; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Triazoles | 2019 |
Molecular targeted therapies in breast cancer: where are we now?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Chemotherapy, Adjuvant; ErbB Receptors; Female; Genes, erbB-2; Humans; Lapatinib; Quinazolines; Receptors, Estrogen; Tamoxifen; Trastuzumab | 2007 |
A multidisciplinary approach to the management of breast cancer, part 2: therapeutic considerations.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Brachytherapy; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Chemotherapy, Adjuvant; Combined Modality Therapy; Cytochrome P-450 CYP2D6; Genes, erbB-2; Humans; Lapatinib; Male; Mastectomy; Pharmacogenetics; Quinazolines; Radiation Dosage; Tamoxifen; Trastuzumab; Treatment Outcome | 2007 |
Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Female; Fluorouracil; Genes, erbB-2; Humans; Lapatinib; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Tamoxifen; Time Factors; Trastuzumab | 2008 |
Costs of adjuvant breast cancer treatments.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Health Care Costs; Humans; Lapatinib; Quinazolines; Tamoxifen; Trastuzumab | 2009 |
[Novel targeted drug therapies in breast cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bevacizumab; Breast Neoplasms; Female; Humans; Lapatinib; Quinazolines; Tamoxifen; Trastuzumab | 2010 |
Use of molecular markers for predicting therapy response in cancer patients.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers; Breast Neoplasms; Cytochrome P-450 CYP2D6; ErbB Receptors; Female; Genotype; Humans; Lapatinib; Mutation; Precision Medicine; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Trastuzumab | 2011 |
[Progress of molecularly targeted therapy for breast cancer].
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Denosumab; Drug Design; Drug Therapy, Combination; Everolimus; Humans; Lapatinib; Letrozole; Maytansine; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Sirolimus; Tamoxifen; Trastuzumab; Triazoles | 2012 |
Co-targeting estrogen receptor and HER2 pathways in breast cancer.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; Trastuzumab; Triazoles | 2014 |
Adjuvant systemic therapy in breast cancer: quo vadis?
Topics: Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Mastectomy; Paclitaxel; Patient Selection; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Tamoxifen; Trastuzumab; Triple Negative Breast Neoplasms | 2015 |
3 trial(s) available for lapatinib and tamoxifen
| Article | Year |
|---|---|
Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Carcinoma, Renal Cell; Disease-Free Survival; ErbB Receptors; Female; Humans; Immunohistochemistry; Kidney Neoplasms; Lapatinib; Male; Megestrol Acetate; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Tamoxifen | 2008 |
Markers of systemic inflammation predict survival in patients with advanced renal cell cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Humans; Inflammation; Kaplan-Meier Estimate; Kidney Neoplasms; Lapatinib; Leukocyte Count; Male; Megestrol Acetate; Middle Aged; Platelet Count; Prognosis; Quinazolines; Serum Albumin; Tamoxifen; Young Adult | 2013 |
A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053 Lapatam study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome | 2014 |
24 other study(ies) available for lapatinib and tamoxifen
| Article | Year |
|---|---|
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Potent antiproliferative activity of bradykinin B2 receptor selective agonist FR-190997 and analogue structures thereof: A paradox resolved?
Topics: Anti-Bacterial Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; MCF-7 Cells; Quinolines; Receptor, Bradykinin B2 | 2021 |
The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.
Topics: Breast Neoplasms; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Estrogen Receptor Modulators; Estrogens; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Tamoxifen | 2005 |
San Antonio Breast Cancer Symposium.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Diphosphonates; Everolimus; Female; Humans; Imidazoles; Lapatinib; Letrozole; Nitriles; Quinazolines; Sirolimus; Tamoxifen; Trastuzumab; Triazoles; Zoledronic Acid | 2009 |
Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Ki-67 Antigen; Lapatinib; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoadjuvant Therapy; Nitriles; Predictive Value of Tests; Preoperative Period; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estrogen Antagonists; Female; Gene Expression; Humans; Lapatinib; Mice; Mice, Nude; Molecular Targeted Therapy; Mucin-4; Oligonucleotide Array Sequence Analysis; Phenotype; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Statistics, Nonparametric; Tamoxifen; Transcriptome; Trastuzumab; Tumor Burden; Up-Regulation; Xenograft Model Antitumor Assays | 2012 |
Biological subtypes and survival outcomes in breast cancer patients with brain metastases (study of the Anatolian Society of Medical Oncology).
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Multivariate Analysis; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Tamoxifen; Trastuzumab; Turkey | 2012 |
BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Disease-Free Survival; Drug Resistance, Neoplasm; Estrogen Receptor Modulators; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Middle Aged; Molecular Targeted Therapy; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Long Noncoding; RNA, Messenger; RNA, Untranslated; Signal Transduction; Tamoxifen | 2012 |
Differential scanning calorimetry as a tool to investigate the transfer of anticancer drugs to biomembrane model.
Topics: Antineoplastic Agents; Biological Transport; Calorimetry, Differential Scanning; Cell Membrane; Cold Temperature; Dimyristoylphosphatidylcholine; Docetaxel; Drug Delivery Systems; Hot Temperature; Injections; Lapatinib; Liposomes; Membranes, Artificial; Neoplasms; Phospholipids; Quinazolines; Tamoxifen; Taxoids | 2013 |
Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Estradiol; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; MCF-7 Cells; Mice; Mice, Nude; Quinazolines; Random Allocation; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Tamoxifen; Up-Regulation; Xenograft Model Antitumor Assays | 2014 |
Targeting connexin 43 with α-connexin carboxyl-terminal (ACT1) peptide enhances the activity of the targeted inhibitors, tamoxifen and lapatinib, in breast cancer: clinical implication for ACT1.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Connexin 43; Drug Delivery Systems; Female; Humans; Lapatinib; Quinazolines; Tamoxifen; Tumor Necrosis Factor Receptor-Associated Peptides and Proteins | 2015 |
Hedgehog Acyltransferase as a target in estrogen receptor positive, HER2 amplified, and tamoxifen resistant breast cancer cells.
Topics: Acyltransferases; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Estrogen Receptor alpha; Female; Gene Amplification; Hedgehog Proteins; Humans; Lapatinib; Protein Transport; Quinazolines; Receptor, ErbB-2; Signal Transduction; Tamoxifen | 2015 |
Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Case-Control Studies; Clonal Evolution; Deoxycytidine; DNA, Neoplasm; Female; Gemcitabine; Humans; Lapatinib; Liver Neoplasms; Lung Neoplasms; Mutation; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Sequence Analysis, DNA; Spinal Neoplasms; Tamoxifen; Trastuzumab | 2015 |
Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Resistance, Neoplasm; Enzyme Induction; ErbB Receptors; Estradiol; Female; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Genes, erbB-2; Humans; Lapatinib; MCF-7 Cells; Metformin; Neoplasm Proteins; Neuregulin-1; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; RNA Interference; RNA, Small Interfering; Signal Transduction; Tamoxifen; Tumor Stem Cell Assay | 2016 |
Synergistic disruption of ERα/HER2 crosstalk by endoxifen and lapatinib in breast cancer cells.
Topics: Activation, Metabolic; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cytochrome P-450 CYP3A; Drug Synergism; Estrogen Receptor alpha; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Tamoxifen | 2017 |
Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carrier Proteins; Cell Line, Tumor; Dasatinib; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Lapatinib; Mice; Mice, Nude; Oncogene Proteins, Fusion; Receptor, ErbB-2; Signal Transduction; src-Family Kinases; Tamoxifen; Xenograft Model Antitumor Assays | 2020 |
Tamoxifen overcomes the trastuzumab-resistance of SK-BR-3 tumorspheres by targeting crosstalk between cytoplasmic estrogen receptor α and the EGFR/HER2 signaling pathway.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immunological; Breast Neoplasms; Cell Line, Tumor; Cytoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Estradiol; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Receptor, ErbB-2; Signal Transduction; Tamoxifen; Trastuzumab | 2021 |
A case study of a patient-centered reverse translational systems-based approach to understand adverse event profiles in drug development.
Topics: Cardiotoxicity; Doxorubicin; Drug Development; Drug-Related Side Effects and Adverse Reactions; Humans; Lapatinib; Paroxetine; Patient-Centered Care; Tamoxifen; Trastuzumab | 2022 |
Analyses of Ocular Adverse Reactions Associated With Anticancer Drugs Based on the Japanese Pharmacovigilance Database.
Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Humans; Imatinib Mesylate; Japan; Lapatinib; Pharmacovigilance; Tamoxifen | 2022 |
Evaluation of the Sensitivity of Breast Cancer Cell Lines to Cardiac Glycosides Unveils ATP1B3 as a Possible Biomarker for the Personalized Treatment of ERα Expressing Breast Cancers.
Topics: Adenosine Triphosphatases; Anastrozole; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Cardiac Glycosides; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Letrozole; MCF-7 Cells; Ouabain; Precision Medicine; Sodium-Potassium-Exchanging ATPase; Tamoxifen | 2022 |